Worldwide CNS Therapeutics Industry to 2025 - Awareness Campaigns Launched by Pharma Companies to Benefit the Market

News provided by

Apr 14, 2021, 15:45 ET

DUBLIN, April 14, 2021 /PRNewswire/ -- The "CNS Therapeutics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

The global market for CNS Therapeutics is projected to reach US$137.7 billion by 2025, driven by the urgent need to address the unmet medical needs of neurological disorders. Diseases of the brain and mind range from epilepsy, stroke, migraine, Alzheimer`s, Parkinson`s, dementia, multiple sclerosis, brain injuries, neuroinfections, schizophrenia, psychosis and other mental disorders. With unmet needs continuing to persist, societal and healthcare burden continues to increase.

Stroke and infections such as meningitis and encephalitis continue to be the leading cause of disability worldwide, pushing up the cost of nursing care, hospice and bringing down quality of life. The unmet needs are evident in all phases of drug development i.e. identification of therapeutic targets; optimization of lead compounds; gaps in toxicity and pharmacokinetics studies; and slow resolution of ethical issues, among others. The need of the hour is innovation in developing more potent drugs and therapies. One of the reasons for the slower development of safe and effective drugs for neurology is the fact that the human brain is one of the most complex and highly organized organs in the universe.

The brain is a highly sophisticated piece of organic system perfected over millions of years of evolution. Scientists continue to struggle to fathom the complex interaction of chemicals and neurons in the brain. Investments in drug development in neurology is risky since certain diseases like neuropsychiatric diseases are difficult to target, are poorly defined, cannot be easily assayed, and pose challenges in efficiently validating clinical efficiency of drugs during clinical trials as most diseases progress slowly and develop over the years.

Strong opportunities for CNS focussed drugs therefore exists and compounding this need is the rapidly aging population and a parallel rise in Parkinson`s, Alzheimer`s, pain manifestations, cerebrovascular disorders, stroke, seizures, cognitive and memory disorders. The scenario has created a healthy global pipeline of late stage drugs and the market is expected to benefit from rising acceptance of new therapies and new classes of drugs; increased demand for combination therapies; growing use of generics; and launch of new Alzheimer`s drugs including anti-amyloid proteins, cholinergic and nicotine receptor agonists, neuro protective drugs, vaccines and GABA receptor modulators.

A key trend in the market is pharma companies` efforts to restrategize CNS drug development, which still continues to cost significantly higher than development costs in other therapeutic areas. Increased use of contract research organization services; and predictive planning to prevent late stage drug failure are few of the strategies adopted to infuse vigor in the CNS drug development space. The United States and Europe represent large markets worldwide with a combined share of 70% of the market. China ranks as the fastest growing market with a CAGR of 7.3% over the analysis period supported by factors such as changing social structures and increased risk of developing psychiatric disorders such as schizophrenia, sleep disorders, depression and anxiety; growing literacy rates, improved awareness and gradual reduction in the stigma associated with neurological disorders; and government policy led development of healthcare delivery systems.

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Central Nervous System (CNS) Therapeutics: A Prelude
CNS Therapeutics Exhibit Robust Opportunities amidst Rising Incidence of CNS Disorders
List of FDA Approved CNS Drugs: 2019
List of FDA Approved CNS Drugs: 2018
Patent Expiries of Major Drugs Exert Downward Pressure on the Global CNS Market
Patent Expiries of Leading CNS Drugs: 2008-2022
Developed Markets to Maintain their Dominance
Developing Market to Drive the Market Momentum
MARKET ANALYSIS BY THERAPEUTIC CATEGORY
Anti-Epilepsy Market
Global Market Overview
Regional Landscape
Developed Countries Account for a Major Share of Epilepsy Treatment
Developing Countries Struggle with Low Treatment Rates
New Approvals (2019 and 2018)
Disease Overview
Degenerative, Infective, Neoplastic, Trauma, and Vascular Epilepsy
High Unmet Needs Offer Scope for Market Growth
Treatment
Anti-Epileptic Drugs (AEDs) by Generic Name and Brand Names
Leading Anti-Epileptic Drugs
Leading Anti-Epileptic Drugs and Their Mechanism of Action
Patent Expiries of Major Anti-Epilepsy Drugs
FDA's New Policy for AED Drugs to Bolster Market Growth
AAN Updated Guidelines on New AEDs Use for Treating New Onset Epilepsy (2019)
Select Currently Available Epilepsy Drugs
Select Anti-Epilepsy Drugs (AEDs) in Phase III Trials
Innovative Drugs Needed for Better Treatment Compliance
Abounding Potential for NCEs
A New Research Demonstrates Effectiveness of Gluconate in Treating Neonatal Seizures
FDA Approves Epidiolex (Cannabidiol) - First Drug for Treating Dravet Syndrome and Lennox-Gastaut Syndrome
Refractory Childhood Epilepsy & Pregnancy Epilepsy - Major Concerns
Recent Approvals for Childhood Epilepsy: 2016-2019
Review of Anti-Epilepsy Drugs
Vimpat
Keppra
Lamictal
Tegretol
Sabril
Perampanel
Zonegran
Topamax
Trileptal
Neurontin
Lyrica
Depakine
CNS Pain Management
Market Overview
Treatment
Drugs Indicated for Pain Management
Select Phase III Ongoing Studies for Cancer Pain
Regional Overview
Players
Combination Therapies Gain Prominence
Key Trends in Chronic Pain Management
Neuropathic Pain Management: Market with High Potential
Select Phase III Ongoing Studies for Neuropathic Pain
Lyrica's Generics Gain FDA Approval
Migraine Market: A Core Vertical in CNS Pain Management
Migraine Care: Select Patent Expiries (2013-2015)
Migraine Completed Phase III Studies: As of October 2019
Migraine Ongoing Phase III Studies: As of October 2019
Select Pain Management Drugs
Flupirtine
Lyrica
Oxycodone
Nucynta ER
Metabotropic Glutamate Receptors (mGluRs)
New Pain Management Drugs
Novartis Presents New Data for Aimovig
Reyvow, Eli Lilly's Novel Migraine Drug with the Potential to Lead the Global Migraine Medications Market
Three New Migraine Drugs Obtain FDA Approval
Eli Lilly's Emgality Receives FDA Approval
Anti-Alzheimer's
Market Overview
Alzheimer's Phase III Completed Studies
Alzheimer's Phase III Ongoing Studies
Treatment for Alzheimer's
Select Leading Drugs for Alzheimer's Disease by Drug Category
Patent Expiries of Leading Alzheimer's Drugs
Aducanumab Marches towards FDA Approval, Following being Abondoned by Biogen a few Months Ago
The Clinical Trials for Aducanumab
Aducanumab: A Promising Drug Which would Revolutionalize the Alzheimer's Market
Alzheimer's Drugs: A Market Plagued with Failures
Promising Compounds with Silver Lining
PRI-002 Gains Success in First Stage of Human Testing for Alzheimer's Disease
Updated FDA Standards Make Way for Increased Alzheimer's Drug Testing
Rising Discontinuation of BACE Programs for Alzheimer's to Dampen Market Growth
Rising Discontinuation of BACE Programs for Alzheimer's to Dampen Market Growth
Elenbecestat's Phase 3 Trials Halted
Novel Drug Delivery Method to the Brain Discovered
Alzheimer's Association Provides Grant to Longeveron
A Review of Select Anti-Alzheimer's Drugs
Aricept
Exelon
Reminyl
Ebixa
Namenda
A Review of the Alzheimer's disease
Alzheimer's Effect on Brain
Causes for Alzheimer's
Who Are at Risk?
Prevalence of Alzheimer's Disease
Diagnosis of Alzheimer's
Anti-Parkinson's
Market Overview
Nourianz, An Add-on Medication for Treating Episodes of Parkinson's Disease Secures FDA Approval
Recent Approvals
Novel Drug and a New Delivery Method for Restoring Brain Cells in People Suffering from PD
Xadago - Add-On Therapy for Parkinson's Disease
NUPLAZID - The First and the Only Approved Drug for Psychosis related to Parkinson's disease
Parkinson's Phase III Completed Studies: As of October 2019
Parkinson's Ongoing Phase III Studies: As of October 2019
Select Anti-Parkinson's Drugs
Levodopa
Dopamine Agonists
Mirapex
FDA Announces Imminent Discontinuation of Certain Formulations of GSK's Requip for PD and RSL Treatment
A Review of the Parkinson's Disease
Prevalence
Symptoms
Causes
Diagnosis
Anti-Depressants
Market Overview
Exhibit 5: Anti-Depressant Market: Percentage Share Breakdown by Depressive Disorder Type
Anti-Depressant Treatment
Exhibit 6: Select Top Selling Anti-Depressants in 2018
Select Antidepressants Drugs
Zoloft (Sertraline)
Cymbalta
Prozac (Fluoxetine)
Effexor (Venlafaxine)
Paxil
Wellbutrin (Bupropion)
Recent Approvals of Anti-Depressants
Esketamine, the Fast Acting Drug for Depression from Janssen Receives FDA Approval
Pipeline Drugs in Phase III for Depressive Disorder: As of October 2019
A Review of Depression
Prevalence of Depression
Causes of Depression
Types of Depressive Disorders
Available Treatment
Tricyclic Antidepressants
Monoamine Oxidase Inhibitors
Lithium Salts
Working of Antidepressants
Ranking of Antidepressants in Terms of Efficacy
Types of Antidepressants
NMDA Receptor Antagonists
NMDA Receptor (NMDAR)
NMDA Receptor Agonists
Acetylcholinesterase Inhibitors
Selective Serotonin Reuptake Inhibitors (SSRIs)
Workings of SSRIs
Safety Levels of SSRI Drugs
Adverse Effects of SSRI
Serotonin Noradrenaline Reuptake Inhibitors (SNRIs)
Anti-Psychotics
Market Overview
Leading Atypical Antipsychotics for the Treatment of Schizophrenia
Pipeline Drugs in Phase III for Schizophrenia: As of October 2019
Pipeline Drugs in Phase III for Bipolar Disorder: As of October 2019
Select Anti-Psychotic Drugs
Zyprexa
Seroquel
Abilify
Clozaril
Risperdal
Risperdal Consta
Geodon
Invega Sustenna
Saphris
Latuda
A Review of Anti-Psychotics
Indications of Antipsychotics
An Effective Adjunctive Therapy
Off-label Uses
Efficacy - Marred by Lack of Evidence Base
Types of Antipsychotics
Difference between Typical and Atypical
Atypical Antipsychotics Up Against Typicals
Side Effects of Antipsychotics
Symptoms of Antipsychotics Withdrawal
Bipolar Disorder
Symptoms of Bipolar Disorder
Mood Episode - A Major Symptom
Manic Episode Vs Depressive Episode
Causes of Bipolar Disorder
Types of Bipolar Disorder
Co-morbidities of Bipolar Disorder
Schizophrenia
Prevalence by Gender
Symptoms of Schizophrenia
Causes of Schizophrenia
Other CNS Disorders (Multiple Sclerosis, Attention Deficit Hyperactivity Disorder (ADHD), and Insomnia)
Multiple Sclerosis (MS)
List of Approved Drugs for MS
Patent Expiration Date/Year of the Major MS Drugs
Exhibit 7: Leading Multiple Sclerosis Drugs (2018): Sales in USD Million
New Approvals
Novartis Receives FDA Approval for Mayzent for Use in Multiple Sclerosis
Mavenclad Gains FDA Approval
Celgene Files NDA for Ozanimod
Ocrevus - The First Approved Drug for Primary Progressive Multiple Sclerosis (PPMS)
Multiple Sclerosis: Pipeline Analysis
Pipeline Drugs in Phase III for Multiple Sclerosis: As of October 2019
A Review of Multiple Sclerosis (MS)
Types of Multiple Sclerosis
Exhibit 8: Clinical Subtypes of Multiple Sclerosis (MS)
Prevalence of MS
Causes of MS
Myths Surrounding Multiple Sclerosis
Symptoms of MS
Diagnosis of MS
Attention Deficit Hyperactivity Disorder (ADHD)
Market Overview
Approved Drugs for ADHD: 2017
Sales of Vyvanse in 2018
Pipeline Drugs in Phase III for ADHD: As of October 2019
Select ADHD Drugs
Vyvanse
Concerta
Adderall
A Review of Attention Deficit Hyperactivity Disorder (ADHD)
Consequences of ADHD
What Leads to ADHD?
Insomnia
Overview
List of Approved Drugs for Insomnia
Pipeline Drugs for Insomnia: As of October 2019
Zolpidem
Eszopiclone
A Review of Insomnia
Prevalence of Insomnia
Therapies for Insomnia

2. FOCUS ON SELECT PLAYERS

AbbVie Inc. (USA)
Alkermes Plc. (Ireland)
Allergan Plc. (Ireland)
AstraZeneca Plc. (UK)
BIAL Group (Portugal)
Bristol-Myers Squibb (USA)
Eisai Co., Ltd. (Japan)
Endo Pharmaceuticals Inc. (USA)
Eli Lilly and Co. (USA)
F. Hoffmann-La Roche Ltd. (Switzerland)
Fabre-Kramer Pharmaceuticals, Inc. (USA)
GlaxoSmithKline (UK)
H. Lundbeck A/S (Denmark)
Johnson & Johnson (USA)
Janssen Pharmaceuticals, Inc. (USA)
Merck & Co., Inc. (USA)
Neurocrine Biosciences, Inc. (USA)
Novartis AG (Switzerland)
Otsuka Pharmaceutical Co., Ltd. (Japan)
Pfizer, Inc. (USA)
Purdue Pharma L.P. (USA)
Sanofi (France)
Sumitomo Dainippon Pharma Co., Ltd. (Japan)
Sunovion Pharmaceuticals, Inc. (USA)
Takeda Pharmaceutical Co., Ltd. (Japan)
Teva Pharmaceutical Industries Ltd. (Israel)
UCB S.A., (Belgium)

3. MARKET TRENDS & DRIVERS

Burgeoning Global Aging Populace, Longer Life Expectancy to Drive CNS Demand
Increased Spending on Prescription Drugs Bodes Well for the CNS Therapeutics Market
Rising Healthcare Expenditure to Boost CNS Therapeutics Market
Growing Middle Class Population in Emerging Regions to Spur the Market
Growing Penetration of Generic Drugs Emerges as a Key Trait
Dollar Spending by Drug Category
Developments in CNS Drug Delivery Technologies Bode Well for the CNS Drugs Market
Understanding of BBB Cell Biology & Its Positive Impact on Epilepsy Drugs: A Case-in-Point
Pharma Companies: Seeking New Tools to Offset Pressure on Drug Pipelines
Awareness Campaigns Launched by Pharma Companies to Benefit the Market.
Music and Memory Programs Positively Impact Alzheimer's Disease (AD) and Related Dementia (ADRD) Patients
New Method to Isolate Active Compounds Related to Alzheimers from Plant Medicines

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

UNITED STATES
Aging Population: A Strong Demographic Driver
Exhibit 15: North American Elderly Population by Age Group (1975-2050)
The Largest CNS Therapeutics Market Globally
Patent Expiries of Leading CNS Drugs in the US
Focus on Select Markets
Alzheimer's Market
Anti-depressant Drugs
Usage of Antidepressants Surges in the US
Anti-Epilepsy Market
Epilepsy - A Major Concern for the Healthcare Industry
A Glance at Epilepsy Statistics
Anti-Epilepsy Drugs
The US Epilepsy Market: Patent Expiry of Select Major Drugs
Epilepsy in Children
Growing Competition from Generics
Pain Management Market
Consumers in the US Seek Different Options for Chronic Pain Management
Neuropathic Pain Market
Anti-Psychotic Drugs Market
Mental Illnesses - Epidemiology
Facts & Figures
Exhibit 16: Lifetime Prevalence (%) of Bipolar Disorder in the US Population by Age Group
Popular Antipsychotic Drugs in the US
Surging Off-label Prescriptions
Generics Occupy Front Seat
Rising Antipsychotic Use among Children - A Cause of Concern
ADHD Market
Select Available ADHD Drugs in the US
Adult ADHD Drugs Continue to Widen their Share
Market Analytics
CANADA
CNS Diseases: Facts & Figures
JAPAN
CHINA
China: The Primary Market for CNS Drugs in Asia-Pacific
Select Anti-Schizophrenia Drugs Available in China
Other Available CNS Drugs in China
EUROPE
European Patent Expiries of Select CNS Drugs
Pain Management Market
Neuropathic Pain Market Witnesses Foray of Generics
Anti-Psychotics Market
Demand for Antipsychotics for Bipolar Disorder Upbeat
Ageing Population Boosts Demand
Exhibit 20: 65+ Population as Percentage of Total Population for Major Countries in Europe: As on June 2019
FRANCE
GERMANY
ITALY
Market Snapshots
UNITED KINGDOM
NICE Recommendations on CNS Therapeutics
SPAIN
RUSSIA
REST OF EUROPE
ASIA-PACIFIC
India & China Offer Significant Growth Opportunities
Growing Antipsychotics Market in Asia

IV. COMPETITION

Total Companies Profiled: 181

For more information about this report visit https://www.researchandmarkets.com/r/5jruqy

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets